REG - Cizzle Biotechnology - Contract in Caribbean and Update on CIZ1B

Cizzle Biotechnology HoldingsAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250428:nRSb3661Ga&default-theme=true

RNS Number : 3661G  Cizzle Biotechnology Holdings PLC  28 April 2025

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
EU REGULATION 596/2014 (WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE
EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("EUWA")) ("UK MAR")

28 April 2025

Cizzle Biotechnology Holdings plc

 

("Cizzle", "Cizzle Biotechnology", or the "Company")

 

First Hospital Laboratory Contract in Caribbean

Update on Launch of CIZ1B Biomarker Assay

Cizzle Biotechnology, the UK based diagnostics developer of early cancer
tests, is pleased to announce that its licensing partner Cizzle Bio Inc ("BIO"
or "Cizzle Bio") has executed its first contract in the Caribbean as part of
the extension to its exclusive licensing and partnership agreement with the
Company for the USA and Canada, as announced on 16 December 2024.  The
non-exclusive Laboratory Services Agreement signed by BIO with Doctors
Hospital (Chrissie Tomlinson Memorial Hospital - CTMH) in the Cayman Islands
triggers the early royalty payments due to the Company from BIO, totalling
US$500,000 in July and September 2025, as part of the advanced minimum royalty
of US$1 million previously all due on 21 January 2026.

 

In addition to this further clinical laboratory appointment, BIO is making
progress in expanding its network across the USA. Its accreditation and launch
plans are now being synchronised to enable a more co-ordinated and
comprehensive campaign to roll out the CIZ1B biomarker test to help detect
early-stage lung cancer.  Cizzle Bio's initial target was to complete CLIA
accreditation and secure the first commercial sale of the CIZ1B biomarker test
by the end of April 2025. As a consequence of this broader campaign, the
launch date has been slightly extended and is now expected to be finalised in
the near term.

 

Key Highlights

 

·    Cizzle Bio appoints first clinical diagnostics laboratory to offer
commercial CIZ1B biomarker testing in the Caribbean triggering early payments
totalling US$250,000 in July 2025 and US$250,000 in September 2025.

 

·    The expansion of BIO's laboratory network follows the ongoing and
successful collaboration between BIO and the Company to ensure the CIZ1B test
for use in helping detect early-stage lung cancer meets the exacting standards
as a laboratory developed test for commercial use. It is expected that further
sites and commercial launch plans will be announced shortly.

 

Background

 

On 21 October 2024 the Company announced an exclusive licensing and
partnership agreement with BIO for its proprietary CIZ1B biomarker test to
help detect early-stage lung cancer, throughout the USA and Canada.  The
Company has since received payments of US$400,000 from initial exclusivity
fees and advanced royalties as part of guaranteed payments totalling US$2.4
million over the period ending April 2027.  The Company extended that
agreement on 16 December 2024 to cover the 14 Sovereign States of the
Caribbean and the Cayman Islands ("Caribbean") and the signing of BIO's first
contract in the Cayman Islands triggers early payments totalling US$250,000 in
July 2025 and US$250,000 in September 2025.

 

BIO's commercial strategy is to work with a number of specialist clinical
laboratories to maximise market penetration and make the CIZ1B biomarker test
available to as many clinicians and patients as possible.  The appointment of
accredited facilities to launch the CIZ1B biomarker test involves evaluation
of a laboratory's operations, including its testing procedures, quality
control, personnel qualifications, and compliance with regulatory
requirements.  The successful completion of the operational and quality
systems programme is required for launching a cost-effective and scalable
version of the CIZ1B biomarker that is commercially scalable and can be rolled
out as a global solution to help reduce premature cancer deaths and improve
survival rates and quality of life for cancer patients.

 

Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said:

 

"The launch programme for our CIZ1B biomarker test to help in the early
diagnosis of lung cancer by  our licensing partner in North America and the
Caribbean continues to progress at pace and I am delighted to announce its
success in appointing a further clinical laboratory as part of its strategy to
build a network of accredited laboratories to make our innovative cancer test
available to as many clinicians and patients as possible. As part of the
Company's global licensing strategy to deliver shareholder value through
royalty payments and potential benefits arising from equity participation in
the partner companies where possible, by securing its first contract in the
Caribbean, this also facilitates early royalty payments generating early
revenues to the Company. We look forward to sharing updates on the expansion
of sites and reporting on the success of the first commercially available
tests in the near future."

 

 

Enquiries:

 

 Cizzle Biotechnology Holdings plc  Via IFC Advisory
 Allan Syms (Executive Chairman)

 

 Allenby Capital Limited                                       +44(0) 20 3328 5656
 John Depasquale / Piers Shimwell (Corporate Finance)
 Stefano Aquilino / Amrit Nahal (Sales and Corporate Broking)

 

 IFC Advisory Limited            +44(0) 20 3934 6630
 Tim Metcalfe
 Florence Chandler

 

About Cizzle Biotechnology

 

Based on the pioneering work of Professor Coverley and colleagues, on a
naturally occurring variant of the cell nuclear protein CIZ1, the CIZ1B
biomarker is highly associated with the presence of early-stage cancer. The
company has developed CIZ1B into a non-invasive, cost-effective blood test to
help in the early detection of lung cancer and has now entered commercial
royalty-bearing arrangements to license its proprietary technology, and into
collaborations with centres of excellence in cancer care.  Cizzle was
admitted to the Standard segment of the main market of the London Stock
Exchange in May 2021.

 

For more information, please see https://cizzlebiotechnology.com
(https://cizzlebiotechnology.com)

 

You can also follow the Company through its twitter account @CizzlePlc and on
LinkedIn.

 

About Cizzle Bio

 

Cizzle Bio Inc, a company registered in Texas USA, stands at the forefront of
biotechnological innovation, dedicated to revolutionizing the detection of
lung cancer through groundbreaking diagnostic tools. With exclusive rights to
detect the CIZ1B Biomarker in the USA and Canada, we are driven by a
commitment to improve early cancer detection and enhance patient outcomes.

 

For more information, please see https://cizzlebio.com (https://cizzlebio.com)

 

About Doctors Hospital

Founded in 2000 as the Chrissie Tomlinson Memorial Hospital (CTMH) and located
in the heart of George Town, Grand Cayman, Doctors Hospital is the leading
provider of international-standard, private-sector hospital and healthcare
services in the Caribbean.  The Mission of Doctors Hospital is to promote the
health and well-being of all we serve through the provision of First World,
International Standard Healthcare Services in collaboration with all
physicians and other providers who share the same vision and values.

For more information, please see https://www.doctorshospital.ky
(https://www.doctorshospital.ky)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDUBRKRVKUSUAR